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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the efficacy of current, relevant interventions to prevent preterm birth in women with singleton pregnancy and high individual
risk of spontaneous preterm birth. We will consider interventions for women with a history of spontaneous preterm birth or short cervical
length and women with asymptomatic vaginal infections.
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B A C K G R O U N D
Description of the condition
Preterm birth is birth before 37 weeks’ gestation, or 259 days of
pregnancy (Anonymous 1977). Preterm birth and its complications
contribute to neonatal deaths worldwide (Blencowe 2013), and sur-
viving infants may suffer long-term disability, including increased
risk of autism and problems with cognitive function and learn-
ing even into adulthood (Johnson 2014; Linsell 2018; Liu 2015;
Mackay 2010). Provider-initiated preterm birth occurs when preg-
nant women undergo labour induction or caesarean section for se-
vere maternal or fetal complications during pregnancy. In contrast,
spontaneous preterm birth is unplanned birth and should be pre-
vented, provided it is safe to do so (Villar 2012). Many clinical in-
terventions aim to prevent spontaneous preterm birth, and preg-
nant women and healthcare providers alike may consider the ben-
efits and risks of several different treatment options. Both the Unit-
ed Nations and the World Health Organization view preterm birth
research as a priority (Lawn 2016; Yoshida 2016). The UK Govern-
ment also recognises that a reduction in preterm births is critical
for achieving the national Maternity Safety Ambition (DHSC 2017).
Several known characteristics of pregnant women are associated
with higher risk of preterm birth. Pregnant women with a short
cervix, less than 25 mm detected on ultrasound between 18 and
24 weeks' gestation, women with a previous pregnancy that ended
in preterm birth, and those identified as having an asymptomatic
vaginal infection would each be at 'high risk' of preterm birth (Iams
1996). Our systematic review and network meta-analysis will focus
on treatments to prevent preterm birth for women with singleton
pregnancy and high risk of preterm birth.
Description of the intervention
Our study will include interventions that work in different ways to
prevent spontaneous preterm birth in high-risk pregnant women.
To manage the number of possible interventions we include in
the network, we conducted a preliminary (or scoping) of the tri-
al reports allocated to the preterm birth prevention section of the
Cochrane Pregnancy and Childbirth topics list. We considered in-
terventions to be 'active' areas for preterm birth research if we
found three potentially relevant trials of an intervention to prevent
preterm birth published within the last 10 years; these are the inter-
ventions we will include in our network, as named below.
Examples of current, relevant interventions that are well known
as active areas for preterm birth research include cervical cer-
clage and cervical pessary; both of these treatments aim to sup-
port the cervix mechanically to prevent cervical dilation and con-
sequent preterm birth. Another commonly evaluated intervention
to prevent preterm birth is progesterone, a hormone responsible
for maintaining pregnancy. Progesterone may be administered to
women orally, via an intramuscular injection or as a vaginal gel
or tablet. Other interventions of interest aim to discourage uter-
ine contractions (e.g. prophylactic tocolytics or bed rest) or to treat
the vaginal infections that may be associated with spontaneous
preterm birth (e.g. antibiotics or probiotics). Finally, we will include
omega 3, zinc and aspirin because each is an active area for preterm
birth research. A recent Cochrane systematic review of omega 3
showed potential to prevent preterm birth (Middleton 2018). A re-
cent Cochrane overview of preterm birth interventions identified
zinc supplementation to have clear evidence of benefit and aspirin
as a new area of research interest (Medley 2018).
Our review will not include interventions administered to a commu-
nity, or to an unselected, general population of pregnant women.
We want to review treatments that aim to prevent preterm birth in
women identified to be at high risk. Our network will not include
public health treatments like malaria prophylaxis or vitamin sup-
plements when distributed to whole communities to improve the
health of all pregnant women.
How the intervention might work
Current understanding of the biology of preterm birth is incomplete
(Ferrero 2016). Preterm birth is as a result of diverse factors, in-
cluding genetics (Villar 2012). Many interventions for spontaneous
preterm birth target local or systemic inflammation or infection; ex-
amples include antibiotics, probiotics and even possibly omega 3.
The precise mechanisms of infection-related preterm birth are not
known, but experts agree that different pregnant women may have
different responses to treatment of vaginal infections. There may
be no straightforward relationship between 'fewer bugs' and fewer
preterm births (Klebanoff 2018). Other interventions in our network
target uterine muscle contraction or the early, mechanical opening
of the cervix; examples are tocolytics, cervical cerclage and cervi-
cal pessary. Progesterone is a hormone responsible for maintaining
pregnancy, and its absence is believed to initiate labour. The ratio-
nale for investigating low-dose aspirin to prevent preterm birth in-
volves its anti-inflammatory properties and its success in reducing
pre-eclampsia and associated preterm birth (Andrikopoulou 2018).
Future updates of this review may incorporate new interven-
tions along these uterine-contraction or infection-related biologi-
cal pathways or follow new pathways that emerge with more so-
phisticated phenotyping and a better understanding of the causes
of preterm birth. Experts view new translational research into the
biology of preterm birth and the development of new clinical inter-
ventions as critically important and urgent (Martin 2017).
Why it is important to do this review
There are multiple potential treatments for women with singleton
pregnancy and high risk of spontaneous preterm birth. Our review
will rank interventions to identify the most effective strategies for
two populations of women at risk: pregnant women with a histo-
ry of spontaneous preterm birth or short cervical length, and preg-
nant women at risk due to the presence of asymptomatic vaginal
infections. We aim to synthesize all relevant evidence to inform clin-
ical decision making and to improve women's antenatal care.
O B J E C T I V E S
To compare the efficacy of current, relevant interventions to pre-
vent preterm birth in women with singleton pregnancy and high in-
dividual risk of spontaneous preterm birth. We will consider inter-
ventions for women with a history of spontaneous preterm birth or
short cervical length and women with asymptomatic vaginal infec-
tions.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Eligible study types are randomised controlled trials (RCTs), includ-
ing quasi-RCTs and cluster-RCTs. We will include studies published
in abstract form only and eligible unpublished data obtained di-






Eligible pregnant women who are at high risk of spontaneous
preterm birth due to individual risk factors, including:
1. pregnancy history, such as prior spontaneous preterm birth,
midtrimester loss, or cervical insufficiency due to cervical
surgery or any known uterine anomalies;
2. biomarkers relevant to spontaneous preterm birth, such as
short cervical length on ultrasound.
Network 2
Eligible pregnant women who have risk factors for preterm birth di-
rectly linked to vaginal infection:
1. a positive urine culture or vaginal swab indicating asympto-
matic infection during pregnancy;
2. eligible vaginal infections are bacterial vaginosis, chlamy-
dia, ureaplasma, gonorrhoea, group B streptococcus or tri-
chomonas vaginalis;
3. pregnant women with symptomatic infections are not eligible.
Trial inclusion criteria
To be eligible, clinical trials must test a named intervention listed
below to prevent preterm birth in a population of pregnant women
at risk of preterm birth due to pregnancy history or to the presence
of an asymptomatic vaginal infection. Clinical trials of community
and public health-level interventions and trials that target an uns-
elected or mixed-risk population of pregnant women are not eligi-
ble. Trials of interventions applied before conception are not eligi-
ble; nor are trials of clinical assessment strategies.
Clinical trials with biomarkers as the primary or only collected trial
outcome are not eligible (i.e. the effect of an agent on cytokines as
a proxy for elevated preterm birth risk, or trials of antibiotic treat-
ment for bacterial vaginosis that collect and report only cure rate).
Clinical trials of the named interventions used for other purposes
than preterm birth prevention will also be excluded (i.e. trials of
omega 3 for glycaemic control or gestational diabetes).
Network inclusion criteria
We do not expect any included clinical trials to be eligible for inclu-
sion in both network analyses, because the networks outline differ-
ent pregnant populations. As described above, Network 1 will in-
clude women with a history of spontaneous preterm birth or short
cervical length on ultrasound, or both. Network 2 will compare
treatments for women with the named, asymptomatic vaginal in-
fections.
Exclusion criteria
Women with the following characteristics are excluded.
1. Women with multiple pregnancy
2. Women with signs of preterm labour (e.g. regular contractions
or vaginal bleeding)
3. Women with preterm prelabour rupture of membranes (PPROM)
4. Women with obvious symptoms of infection
5. Women with pre-eclampsia or other known maternal conditions
during pregnancy that may lead to planned preterm birth
Women at risk of preterm birth solely due to population risks are
not eligible. Women at risk of preterm birth solely due to elevated
fetal fibronectin alone are also not eligible. Women who have un-
dergone artificial reproductive technologies (ART) during the cur-
rent pregnancy are eligible if they have a history- or infection-relat-
ed risk factor for spontaneous preterm birth.
Types of interventions
Interventions of direct interest
We plan to include trials of the following treatments for pregnant
women at high risk of spontaneous preterm birth who meet the in-
clusion criteria above.
1. Antibiotic treatment for asymptomatic vaginal infections, in-
cluding bacterial vaginosis, chlamydia, ureaplasma, gonor-
rhoea, group B streptococcus or trichomonas vaginalis
2. Aspirin (low-dose)
3. Bed rest
4. Cervical cerclage (described as McDonald, Shirodkar or simply
'cerclage'; we will exclude trials of 'double cerclage', 'cerclage
with occlusion' or cerclage trials comparing suture materials)
5. Cervical pessary (Arabin pessary or similar)
6. Fish oils or omega fatty acids
7. Nutritional supplements (zinc)
8. Probiotics
9. Progesterone (intramuscular, oral or vaginal)
10.Prophylactic antibiotics
11.Prophylactic tocolytics (excluding maintenance therapies)
12.Combinations of eligible interventions
For all included treatments, where feasible we will consider differ-
ences in type, dose and route of administration as separate nodes
in the network (i.e. type of cerclage, progesterone, antibiotic, nutri-
tional supplement or tocolytic). Eligible trials may compare single
or combined active interventions with other active interventions,
with placebo or with no treatment.
We will combine the placebo and no treatment as a single 'control'
node in the networks.
Types of outcome measures
We will summarise clinical trial evidence for the core outcome do-
mains identified in the core outcome set (COS) for preterm birth
(Van't HooM 2016). For pregnant women these are: maternal mor-
tality, maternal infection or inflammation, prelabour rupture of
Interventions to prevent spontaneous preterm birth in high-risk women with singleton pregnancy: a systematic review and network
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membranes, and harm to mother from the intervention. For off-
spring, outcome domains include: gestational age at birth, off-
spring mortality, birthweight, early neurodevelopmental morbidi-
ty, late neurodevelopmental morbidity, gastrointestinal morbidity,
infection, respiratory morbidity, and harm to offspring from the in-
tervention.
Review primary outcomes are two preterm birth time points:
preterm birth less than 34 weeks' gestation and spontaneous
preterm birth less than 34 weeks' gestation, both reported as a pro-
portion.
Outcome measures to capture COS domains for pregnant women:
1. preterm birth less than 37 weeks' gestation;
2. preterm birth less than 34 weeks' gestation;
3. spontaneous preterm birth less than 34 weeks' gestation;
4. preterm birth less than 28 weeks' gestation;
5. maternal death;
6. preterm prelabour rupture of membranes;
7. maternal infection (maternal sepsis or any infection requiring
antibiotics other than sepsis, or both);
8. maternal harm from the intervention (as reported in trials).
Outcome measures to capture COS domains for offspring:
1. perinatal death (fetal death at 22 weeks or later excluding ter-
mination of pregnancy for medical reasons; and neonatal death
as defined below);
2. neonatal death (death of the neonate of 22 weeks' gestation or
later, from birth to 28 days);
3. gestational age at birth;
4. low birthweight, less than 2500 g;
5. neonatal respiratory distress syndrome;
6. neonatal pulmonary disease (defined as the need for ventilation
≥ 24 hours, duration of ventilation in days, or oxygen therapy ≥
36 weeks);





11.admission to neonatal intensive care unit;
12.neonatal harm from the intervention (as reported in trials).
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, on-
going). We will search Cochrane Pregnancy and Childbirth’s Trials
Register by contacting their Information Specialist.
The Register is a database containing over 25,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used to
populate Pregnancy and Childbirth’s Trials Register including the
detailed search strategies for CENTRAL, MEDLINE, Embase and CI-
NAHL; the list of handsearched journals and conference proceed-
ings, and the list of journals reviewed via the current awareness ser-
vice, please follow this link.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials iden-
tified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major con-
ferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is then
added to the Register. The Information Specialist searches the Reg-
ister for each review using this topic number rather than keywords.
This results in a more specific search set that will be fully account-
ed for in the relevant review sections (Included, Excluded, Awaiting
Classification or Ongoing).
In addition to searches via the Information Specialist, we will search
ClinicalTrials.gov and the WHO International Clinical Trials Registry
Platform (ICTRP) for unpublished, planned and ongoing trial re-
ports using transparent search methods based on key terms (see:
Appendix 1 for draM search methods. We will report the full search
methods in the review).
Searching other resources
Conference proceedings
The standard searches described above include conference pro-
ceedings, but we will ensure that the search includes abstracts for
the following conferences: the Society for Maternal and Fetal Med-
icine, the International Federation of Gynecology and Obstetrics
and the American College of Obstetrics and Gynecology.
Reference lists
We will check the reference lists of eligible studies and of similar
systematic reviews identified through the above methods.
We will not apply any language or date restrictions.
Data collection and analysis
Selection of studies
N Medley (NM) and L Goodfellow (LG) will independently screen the
search results for potentially relevant citations. The authors will
cross check their results and resolve any differences through dis-
cussion among review authors. We will retrieve the full article for ti-
tles deemed to be potentially eligible and NM and LG will indepen-
dently assess the full articles for eligibility using the above criteria
and document reasons for exclusion in tables. We will cross check
Interventions to prevent spontaneous preterm birth in high-risk women with singleton pregnancy: a systematic review and network
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eligibility assessment results and discuss and resolve differences.
We will contact trial authors for more information if eligibility is un-
clear. We will scrutinise included trials to ensure that multiple pub-
lications from the same study are grouped appropriately. A study
flow diagram will report the number of included and excluded stud-
ies at each stage of the selection process.
Data extraction and management
NM will extract data for the included trials using data extraction
forms designed in Excel. The extracted data will be independently
checked and verified by LG with discrepancies resolved by discus-
sion. We will contact trial authors for additional information where
necessary. We will extract data regarding the general characteris-
tics, study design, participants, interventions, outcomes and 'Risk
of bias' details. We will report characteristics of included studies
and 'Risk of bias' decisions in tables and figures. Outcome data will
be reported in forest plots and tables as appropriate.
We plan to cross-check data extracted from trial publications with
publications based on individual patient data (IPD). For example,
we are aware of a study of trials of progesterone by the EPPPIC col-
laboration (Stewart 2017).
Trials that randomised individuals
For each outcome, we will extract the number of participants ran-
domised and the number of participants analysed for each study
arm. For dichotomous outcomes, we will also extract the number of
participants with the event for each study arm. For continuous out-
comes, we will extract the mean and standard deviation for each
study arm. We will extract change scores rather than end values
when they are reported. For count outcomes, we will extract the
number of events and the total person time at risk for each study
arm. If this information is not reported, we will extract the summa-
ry statistics that are presented (e.g. medians and ranges for each
study arm).
Trials that randomised clusters
For cluster-RCTs, we will extract the number of clusters randomised
and number of clusters analysed per study arm as well as the num-
ber of participants randomised and analysed for each arm. We will
also extract the average cluster size and the intra-cluster correla-
tion coefficient. When trials correctly adjusted the analyses for clus-
tering, we will extract the cluster-adjusted measure of treatment
effect and its variance. However, we will extract the same data as
for trials that randomise individuals when trials do not adjust for
clustering.
Potential eect-modifying characteristics
We will extract the following characteristics that have the potential
to alter the intervention effect estimate:
1. previous spontaneous preterm birth (Yang 2016);
2. maternal smoking (Shah 2000);
3. cervical length less than 25 mm (or another cut-oF) (Iams 1996);
4. nulliparity (Salihu 2010);
5. caesarean delivery in the first pregnancy (Wong 2015);
6. birth interval shorter than 18 months (Wong 2015);
7. income in the most deprived 10% group (DHSC 2017; Tay-
lor-Robinson 2011);
8. black race (Goldenberg 2008; Schaaf 2013);
9. periodontal disease (Goldenberg 2008).
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2017). We will resolve any
disagreement by discussion or by involving a third review author. In
addition to the domains explained below, for cluster-RCTs we will
assess recruitment bias, baseline imbalance, loss of clusters, incor-
rect analysis, and comparability with RCTs that randomised indi-
viduals (Higgins 2017).
1. Random sequence generation (checking for possible selection
bias)
We will describe for each included study the method used to gener-
ate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);
• unclear risk of bias.
2. Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation; con-
secutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
3.1. Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if any,
to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies
are at low risk of bias if they were blinded, or if we judge that the
lack of blinding would be unlikely to affect results. We will assess
blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
3.2. Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different
outcomes or classes of outcomes.
Interventions to prevent spontaneous preterm birth in high-risk women with singleton pregnancy: a systematic review and network
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We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
4. Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
data)
We will describe for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or can be supplied by the
trial authors, we will re-include missing data in the analyses which
we undertake.
We will assess methods as:
• low risk of bias (e.g. no or low missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data im-
balanced across groups; ‘as treated’ analysis done with substan-
tial departure of intervention received from that assigned at ran-
domisation);
• unclear risk of bias.
5. Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-spec-
ified outcomes and all expected outcomes of interest to the re-
view have been reported);
• high risk of bias (where not all the study’s pre-specified out-
comes have been reported; one or more reported primary out-
comes were not pre-specified; outcomes of interest are report-
ed incompletely and so cannot be used; study fails to include re-
sults of a key outcome that would have been expected to have
been reported);
• unclear risk of bias.
6. Other bias (checking for bias due to problems not covered by 1
to 5 above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
7. Overall risk of bias
We will make explicit judgements about whether studies are at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017). With
reference to 1 to 6 above, we will assess the likely magnitude and
direction of the bias and whether we consider it is likely to impact
on the findings. We will report results in 'Risk of bias' tables, 'Risk
of bias' summaries and 'Risk of bias' graphs.
We will explore the impact of the level of bias through undertaking
sensitivity analyses (see Sensitivity analysis).
Assessment of the quality of the evidence using the GRADE
approach
There are currently no widely agreed methods for applying the
GRADE approach to the results of NMA. However, we do plan to
assess the credibility of the evidence in the review and produce
a 'Summary of findings' table for the main comparisons for both
planned networks.
We will carry out a threshold analysis to explore how robust the
treatment recommendations are to plausible degrees of bias (Cald-
well 2016). For each pairwise treatment effect for which direct ev-
idence is available, we will replace the observed treatment effect
with a series of 20 alternative values using appropriate step sizes.
For each alternative value, we will determine whether the treat-
ment recommendation from the NMA would be affected.
We will also apply an alternative approach, as proposed by Salanti
2014, to assess the quality of the evidence using a procedure that
is based on methods developed by the GRADE Working Group. Af-
ter assessing the quality of pairwise meta-analyses results using the
methods of the GRADE Working Group, we will assess the results
from NMA. We will assess the quality of the treatment effects and
the treatment rankings separately. For pairwise meta-analyses and
NMA, we will assess five key domains: study limitations, indirect-
ness, inconsistency, imprecision, and publication bias. We will rate
each pairwise meta-analysis and NMA result as high, moderate, low
or very low certainty (Guyatt 2011a; Schünemann 2013).
Measures of treatment e9ect
We will present all results with their 95% credibility intervals. All
review outcomes listed above are dichotomous and presented as
proportions, with the exception of 'gestational age at birth', which
is a continuous outcome reported in trials as days or weeks.
Dichotomous data
For dichotomous outcomes, we will use the odds ratio to compare
treatments.
Continuous data
We will use mean differences for continuous outcomes.
Count data
We have identified no count outcomes. However, if we include
these in future updates of the review, for count outcomes we will
compare treatments using rate ratios.
Relative treatment ranking
For each outcome, we will also calculate the probability that each
treatment is the best (i.e. most effective), second best, third best,
etc. We will report results in rankograms, with one plot per inter-
vention; each plot shows the possible ranks on the x-axis and the
probability on the y-axis.
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Unit of analysis issues
Cluster-randomised trials
If a cluster-RCT did not adjust for clustering in its analysis, we will
attempt to adjust for clustering by multiplying the standard error of
the treatment effect by the square root of the design effect, where
the design effect is calculated as 1+(1+m)*ICC where m is the aver-
age cluster size and ICC is the intra-cluster correlation coefficient.
Equivalently, to adjust for clustering, an effective sample size may
be calculated by dividing the original sample size by the design
effect. For dichotomous outcomes, we will divide the number of
events and the number of participants by the design effect. If the
average cluster size is unknown, it will be estimated by the total
number of clusters and participants. If the ICC is unknown, it will
be estimated from external sources, such as trials with similar clus-
ter sizes and features. If the standard error adjusted for clustering
(adjusted SE), the standard error that is not adjusted for clustering
(SE) and the average cluster size (m) can be obtained from a similar
trial, then we will calculate an approximate ICC.
We will present results from cluster-RCTs that cannot be adjusted
for clustering in an additional table, only because their standard
errors will be artificially narrow.
Studies with multiple treatment groups
We will include trials with multiple arms. If the same trial is includ-
ed in the same pairwise meta-analysis more than once, we will split
the control groups to report a relative effect for each intervention
against the control. NMA models will account for the correlation be-
tween treatment effects from multi-arm trials.
Cross-over trials are not eligible for inclusion in this review. Cross-
over trials are only appropriate for evaluating interventions with a
temporary effect on stable, chronic diseases such as asthma. Cross-
over study designs are not appropriate for the named interventions
above as tested in pregnant women.
Dealing with missing data
We will carry out an available case analysis, such that the analysis
is based on the number of women for whom the outcome was ob-
tained in the trial. For many trials, the denominator used to calcu-
late effectiveness will be the number randomised minus any known
exclusions or missing participants. Using the number of women
analysed as the denominator avoids making assumptions about
whether or not missing women had the outcome.
Assessment of heterogeneity
Fixed-effect and random-effects NMA and pairwise meta-analysis
models will be fitted and compared in terms of the model fit and
complexity. We will assess model fit and complexity of models us-
ing the deviance information criterion DIC (Spiegelhalter 2002). A
model with a smaller DIC will be preferable to a model with a larg-
er DIC but we will not consider meaningful differences of less than
five units. When there is little difference in DIC, we will choose the
simplest model. We will also use the posterior mean of the residual
deviance to compare model fit, with small values indicating an im-
proved fit.
We will estimate the posterior, mean, between-trial variance from
the random-effects models and report it with its 95% credibility in-
terval, with large values indicating heterogeneity.
For each pairwise comparison, we will also assess heterogeneity by
visual inspection of the forest plots to detect qualitative or quan-
titative heterogeneity, calculation of the I2 statistic (Higgins 2003),
and the Chi2 test (Deeks 2017), with a cutoff of P < 0.1 used to indi-
cate statistically significant heterogeneity. In the event of substan-
tial quantitative or qualitative heterogeneity we will not carry out
meta-analysis. Substantial heterogeneity is generally an I2 statistic
greater than 80%, but we will consider analyses on a case-by-case
basis.
For each comparison, we will compare key trial and patient char-
acteristics listed previously as potentially treatment-effect modify-
ing, to identify clinical heterogeneity.
Assessment of inconsistency
For each comparison, we will summarise across trials, key trial and
patient characteristics that could potentially modify the treatment
effects (as listed previously), and tabulate them so that we can com-
pare the characteristics. If the characteristics differ across trials for
a particular comparison, the consistency assumption may not be
feasible.
We will apply node-splitting models for each comparison for which
direct evidence and indirect evidence exists to assess local incon-
sistency and provide estimates of the treatment effects based on
direct evidence and indirect evidence separately (Dias 2010a). We
will assess consistency by comparing the NMA model and node-
splitting models in terms of goodness of fit and the size of the be-
tween-trial variances, and by calculating the Bayesian probability
that the direct and indirect evidence agrees.
We will also fit inconsistency models to assess global inconsistency
and compare them with the NMA model in terms of model fit, the
resulting treatment effects and the between-trial variance. We will
apply the unrelated mean effects model, which is equivalent to the
NMA model but does not make the assumption of consistency (Dias
2013a).
If inconsistency is detected or suspected, we will not report NMA
results; instead, we will explore the cause of the inconsistency and
resolve it, or instead present results from pairwise meta-analysis.
Assessment of reporting biases
For each pairwise comparison, we will assess publication bias by
constructing funnel plots showing trials from direct evidence. For
NMA, we will assess publication bias by applying a regression mod-
el that adjusts for reporting biases. The regression model allows for
an interaction between the observed variance and the treatment
effect (Trinquart 2012). We will also apply an appropriate selection
model to account for publication bias (Mavridis 2014).
Data synthesis
We will construct two different networks as described above, Net-
work 1 and Network 2. The data synthesis methods described be-
low apply to each network.
For each outcome, we will construct a network diagram to display
the treatment comparisons for which direct evidence is available
and the number of trials.
We will apply NMA models and pairwise meta-analysis models to
study arm data except when cluster-RCTs are included in the analy-
Interventions to prevent spontaneous preterm birth in high-risk women with singleton pregnancy: a systematic review and network
meta-analysis (Protocol)









Cochrane Database of Systematic Reviews
sis. When a cluster-RCT is included, we will meta-analyse the clus-
ter-adjusted estimate of the treatment effect and its standard error
with treatment effects and standard errors from other trials. Model
specifications and computer codes are described elsewhere (Dias
2013b).
Models will be fitted using WinBUGS 1.4.3 and the R2WinBUGS
package in R. We will assume the between-trial variance to be equal
across comparisons in NMA models. The parameterisation of the
model will be chosen to be the same for each outcome.
Following a Bayesian framework, we will choose a non-informative
uniform prior distribution for the between-trial standard deviation
of random-effects models. Non-informative Normal prior distribu-
tions will be chosen for all other model parameters. For each mod-
el, we will run three chains with different initial values until conver-
gence is achieved and then we will run a further 100,000 iterations
on which to base results. We will thin results if needed. We will as-
sess convergence of the chains by inspecting plots of the draws.
Subgroup analysis and investigation of heterogeneity
If we detect heterogeneity, we will apply pairwise meta-regression
models; likewise, if we find inconsistency in NMA models, we will
use network meta-regression. Characteristics that we will explore
are listed as potentially treatment-effect modifying in the Data ex-
traction and management section. We will use the size of the re-
gression coefficients for the treatment by covariate interaction and
its credibility interval to determine whether an interaction exists
and, therefore, whether the covariate modifies the treatment ef-
fect. We will also compare model fit statistics (i.e. residual deviance
and the DIC) from meta-regression with the meta-analysis mod-
el to determine the best model. We will tabulate results, includ-
ing posterior median treatment effects, regression coefficients and
their credibility intervals, and presented them graphically (Done-
gan 2018a). We will assess the consistency assumptions that un-
derlie network meta-regression models using node-splitting mod-
els and inconsistency models (Donegan 2018b).
Sensitivity analysis
We will carry out sensitivity analyses for the following outcomes:
any preterm birth less than 34 weeks; spontaneous preterm birth
less than 34 weeks, and perinatal death.
As sensitivity analyses, we will also apply an NMA model that ac-
counts for uncertainty because of missing data by modelling both
the observed and missing data; we will assume no prior informa-
tion with regard to the probability of an event in the missing partic-
ipants (Turner 2015). In a separate analysis, we will also assume a
fixed proportion of those missing has the event (i.e. 10%).
When we have adjusted the results from cluster-RCTs ourselves, we
will carry out sensitivity analyses, excluding the trial for which the
approximation was made.
The NMA models we will apply will assume homogeneous variances
across comparisons. We will also apply an NMA model that assumes
heterogeneous variances and compare the model fit (Lu 2009).
We will estimate and adjust for bias, in terms of risk of bias compo-
nents, such as, allocation concealment, in the network by applying
NMA models that includes bias parameters and a covariate for 'Risk
of bias' judgement (Dias 2010b). We will also carry out sensitivity
analyses based on 'Risk of bias' components (i.e. excluding trials
with high and unclear risk of bias for sequence generation and al-
location concealment).
We will explore novel agent bias, where bias always favours the
newer treatment, by fitting an NMA model that includes bias para-
meters and a covariate indicating whether a study arm is receiving
the newer drug for that particular study (Salanti 2010).
We will assess industry sponsorship bias by applying a similar NMA
bias model with funder (industry versus other) as a covariate (Naci
2014).
Finally, where relevant we will assess the impact of including qua-
si-randomised trials or those reported as abstracts only.
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As part of the pre-publication editorial process, this protocol has
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who are external to the editorial team), a member of Cochrane
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the Group's Statistical Adviser. The authors are grateful to the fol-
lowing peer reviewers for their time and comments: Ioannis Gallos,
Clinician Scientist, Institute of Metabolism and Systems Research
(IMSR), University of Birmingham, Honorary Consultant Obstetri-
cian and Gynaecologist and Subspecialist in Reproductive Med-
icine and Surgery, Birmingham Women's Hospital, UK; Amanda
Johnson, MD, Medical College of Wisconsin; Jennifer McIntosh, DO,
MS, Medical College of Wisconsin; Rachel Plachcinski, consumer
member of the Pregnancy and Childbirth Group.
This project was supported by the National Institute for Health Re-
search, via Cochrane Infrastructure funding to Cochrane Pregnancy
and Childbirth. The views and opinions expressed therein are those
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A P P E N D I C E S
Appendix 1. DraE search methods for ICTRP and ClinicalTrials.gov
ClinicalTrials.gov
Advanced search
prevention | Interventional Studies | Preterm birth
risk | Interventional Studies | Preterm Labor
ICTRP
We will run each line separately
risk AND preterm
risk AND premature
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